Cross-topic event
Lilly and Verve report VERVE-102 base-editing data: up to ~62% LDL-C reduction and up to ~88% PCSK9 lowering after one infusion
May 27, 20262 reports
May 27, 2026
Sciencedesk view
Lilly and Verve report VERVE-102 base-editing data: up to ~62% LDL-C reduction and up to ~88% PCSK9 lowering after one infusion
In a corporate release, Eli Lilly describes interim Phase 1b Heart-2 results for VERVE-102, an in vivo PCSK9 base editor, in 35 adults with heterozygous familia…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
NEJM publishes early PCSK9 base-editing results for VERVE-102
On May 25, 2026, The New England Journal of Medicine posted a phase 1, open-label, dose-escalation study of VERVE-102, an in vivo adenine base editor targeting …
READ THE DAY'S DIGEST →